rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2008-9-1
|
pubmed:abstractText |
We observed 2 cases of Pneumocystis carinii pneumonia (PCP) occurring in HIV-negative patients during treatment with dose-dense chemotherapy with doxorubicin/cyclophosphamide (AC) followed by paclitaxel (T). These represent the first case reports of PCP occurring during dose-dense chemotherapy for breast cancer. Because lymphocyte depletion is thought to predispose patients to PCP, we explored whether the shortened intervals between cycles during dose-dense chemotherapy might place patients at risk for lymphocyte depletion and thereby a potentially increased risk of opportunistic infection.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1526-8209
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
352-6
|
pubmed:dateRevised |
2009-11-30
|
pubmed:meshHeading |
pubmed-meshheading:18757263-Adult,
pubmed-meshheading:18757263-Aged,
pubmed-meshheading:18757263-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18757263-Breast Neoplasms,
pubmed-meshheading:18757263-CD4 Lymphocyte Count,
pubmed-meshheading:18757263-Cohort Studies,
pubmed-meshheading:18757263-Cyclophosphamide,
pubmed-meshheading:18757263-Doxorubicin,
pubmed-meshheading:18757263-Female,
pubmed-meshheading:18757263-Humans,
pubmed-meshheading:18757263-Incidence,
pubmed-meshheading:18757263-Lymphopenia,
pubmed-meshheading:18757263-Middle Aged,
pubmed-meshheading:18757263-Opportunistic Infections,
pubmed-meshheading:18757263-Paclitaxel
|
pubmed:year |
2008
|
pubmed:articleTitle |
Lymphopenia associated with adjuvant anthracycline/ taxane regimens.
|
pubmed:affiliation |
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. stolaney@partners.org
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|